[Corticosteroid therapy: a multidisciplinary approach to patient care?].

As corticosteroids can cause diabetes, it is important to assess the benefit-risk balance for patients before introducing them, and to monitor the development of hyperglycemia in people treated with this therapeutic class. As soon as cortico-induced diabetes is discovered, multidisciplinary, cross-disciplinary management improves follow-up conditions.

Discovery of a TRMT10A mutation in a case of atypical diabetes: Case report.

It is notable that monogenic forms of diabetes are exceedingly uncommon, with only 28 genes thus far identified. Such conditions frequently result in the dysfunction of pancreatic cells responsible for insulin production. Mutation in the TRMT10A gene leads to a rare genetic disease that is associated with endocrine and metabolic disorders, including diabetes and short stature.

Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of anti-diabetic agents that act by inducing insulin secretion and inhibiting glucagon release in a glucose-dependent manner. They are particularly promising because of their long duration of action, reduced risk of hypoglycaemia and the added benefit of weight loss. Trulicity ® dulaglutide is a GLP-1 receptor agonist approved for type II diabetes and chronic weight management in obese adults.